Compare SDA & NNVC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | SDA | NNVC |
|---|---|---|
| Founded | 2007 | 2005 |
| Country | China | United States |
| Employees | 544 | N/A |
| Industry | Blank Checks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 29.6M | 35.2M |
| IPO Year | 2022 | 2008 |
| Metric | SDA | NNVC |
|---|---|---|
| Price | $0.24 | $1.47 |
| Analyst Decision | | Strong Buy |
| Analyst Count | 0 | 2 |
| Target Price | N/A | ★ $6.00 |
| AVG Volume (30 Days) | 151.0K | ★ 290.6K |
| Earning Date | 09-22-2026 | 11-13-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 34.92 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $21.66 | N/A |
| Revenue Next Year | $11.14 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.27 | $0.85 |
| 52 Week High | $2.70 | $2.23 |
| Indicator | SDA | NNVC |
|---|---|---|
| Relative Strength Index (RSI) | 30.18 | 55.56 |
| Support Level | N/A | $1.45 |
| Resistance Level | $0.46 | $1.47 |
| Average True Range (ATR) | 0.06 | 0.11 |
| MACD | -0.00 | 0.01 |
| Stochastic Oscillator | 19.76 | 77.59 |
SunCar Technology Group Inc operates digital automotive aftersales market service platform and vehicle insurance technology platform. It develops and operates online platforms that connect drivers in China with a range of aftermarket automotive services and insurance coverage options from a nationwide network of service providers. These comprehensive digital systems are built on SunCar's multi-tenant, cloud-based platform. Revenues from its continuing operations are mainly generated from providing auto eInsurance services, technology services, and auto services.
Nanoviricides Inc is a nano-biopharmaceutical company that is engaged in discovering, developing, and commercializing therapeutics to advance the care of patients suffering from life-threatening viral infections. The company engaged in the application of nanomedicine technologies to the complex issues of viral diseases. It focuses its research and clinical programs on specific anti-viral therapeutics and is seeking to add to its existing portfolio of products through its internal discovery and clinical development programs and through in-licensing.